.
MergerLinks Header Logo

Announced

Sanofi to invest €300m in Innovent Biologics.

Financials

Edit Data
Transaction Value£251m
Consideration TypeCash
Capital Owned-
Capital Bid For-
EV/Sales-
EV/EBITDA-
Share Price Premium20%
One Off Charge-

Tags

Edit

Pending

Pharmaceuticals

Single Bidder

biopharmaceuticals

Friendly

Minority

Public

China

Cross Border

Acquisition

Synopsis

Edit

Sanofi, a global healthcare company, agreed to invest €300m in Innovent Biologics, a biopharmaceutical company. "This strategic collaboration with Innovent will not only accelerate the development, market access and future commercialization of two of our key oncology medicines in selected combinations with sintilimab, but also bolster our overall presence in oncology in China. We look forward to a successful partnership with Innovent, one of the most innovative companies in China, and to leveraging their development capabilities and market leadership in the country," John Reed, Sanofi Global Head of Research and Development.

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

CONTACT US